Dispatch Bio, a new biotechnology company launched in 2022, revealed a $216 million fundraising milestone alongside its innovative two-component immunotherapy for solid tumors. The platform employs a viral vector delivering a universal antigen called Flare that tags cancer cells while breaking down the tumor environment's immune barriers. Following this, engineered immune cells, including CAR-T therapies, target the marked cancer cells. The biotech is cofounded by immunotherapy pioneers including Carl June and backed by investors like Arch Venture Partners and Parker Institute for Cancer Immunotherapy. Dispatch’s lead program is slated for clinical entry next year and aims to overcome challenges posed by solid tumors’ immunosuppressive microenvironments.